Credit, Getty Images
The use of weight loss drugs known as GLP-1 has gained popularity in recent years.
Beauty giant L'Oréal says the rise in the use of weight-loss drugs has affected sales of beauty and skin care products. The company is developing products specifically aimed at combating some of the side effects of rapid weight loss.
The company's chief executive, Nicolas Hieronimus, stated that the beauty market has demonstrated resilience in a challenging global scenario and that the use of GLP-1 is "a very important phenomenon for us".
In a call with investors, he said the increased use of these medications was "having an impact on the consumption of beauty products and, in particular, the consumption of skin care products."
L'Oréal, owner of other popular brands such as Maybelline and La Roche-Posay, announced on Thursday (22/10) that its sales grew 7.7% in the three months ended in September, exceeding analysts' expectations.
The popularity of GLP-1 has soared in recent years after medications developed to treat diabetes, such as Ozempic, Wegovy and Mounjaro, were also shown to cause significant weight loss by suppressing appetite.
Although it is not an effect caused directly by GLP-1 medications, rapid weight loss can cause sagging skin in some people, including on the face.
Hieronimus stated that the SkinCeuticals and Kiehl's brands, belonging to L'Oréal, offer products "developed to work in conjunction with GLP-1 and complement their effects on sagging skin", in addition to other effects associated with rapid weight loss.
End of Most read
L'Oréal also expanded its operations in the clinical aesthetics segment, increasing its stake in dermatology company Galderma to 20% in December last year.
According to the news agency Reuters, the two companies have been testing products in separate clinical trials with GLP-1 users concerned about sagging skin.
Galderma owns popular aesthetic products, including Sculptra, an injectable designed to stimulate collagen production, and Restylane, an injectable dermal filler.
Last year, the aesthetics company released a report on the increased use of GLP-1 and concerns related to changes in facial appearance.
The company's own survey of users of weight loss medications found that the vast majority had noticed changes in the appearance of their face after using these medications.
Discover more
Watch
End of Watch
